The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Oct. 04, 2022
Filed:
Dec. 23, 2021
King Abdulaziz University, Jeddah, SA;
The Children's Hospital of Philadelphia, Philadelphia, PA (US);
Virginia Commonwealth University, Richmond, VA (US);
Moustafa E. El-Araby, Jeddah, SA;
Abdelsatter M. Omar, Jeddah, SA;
Osheiza Abdulmalik, Philadelphia, PA (US);
Martin K. Safo, Richmond, VA (US);
KING ABDULAZIZ UNIVERSITY, Jeddah, SA;
THE CHILDREN'S HOSPITAL OF PHILADELPHIA, Philadelphia, PA (US);
VIRGINIA COMMONWEALTH UNIVERSITY, Richmond, VA (US);
Abstract
Methods for administering compounds provide a rapid treatment for sickle cell disease (SCD) to inhibit or reverse red blood cell sickling. The compounds are a group of 5-hydroxymethylfurfural (5-HMF) analogs modified to increase water-solubility. The compounds can be formulated in an aqueous carrier and administered intravenously for immediate uptake into red blood cells (RBCs) within hours, rather than days or weeks. In vitro experiments demonstrated rapid uptake into RBCs and increased Oaffinity of HbS to an equilibrium point within 30 to 90 minutes. The compounds have a desired level of safety as well as a short half-life, both of which are compatible with acute usage. Thus, the methods of treatment rapidly achieve therapeutic steady-state drug levels, making it possible to deliver a treatment in critical emergency care situations to prevent, reverse and otherwise treat acute sickling or anemia.